Skip to Main Content

Highlighting concerns with the pharmaceutical supply chain, the Food and Drug Administration warned McKesson, one of the nation’s largest wholesalers, for failing to properly handle episodes where pharmacies received tampered medicines, including three instances in which bottles contained naproxen instead of oxycodone, the highly addictive painkiller.

Specifically, the agency found that McKesson responded inadequately and demonstrated a lack of understanding of key regulations, according to a Feb. 7 warning letter. Notably, the letter is the first such missive issued under the Drug Supply Chain Security Act and also figured prominently in fresh remarks Tuesday by FDA Commissioner Scott Gottlieb about the ongoing opioid crisis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Fines should be set as # of days of GROSS REVENUES, eg, 10 days or 30days or in case of major harm or death, in years or even disincorporation…
    After all, if corporations are “persons”, then let the CEOs serve thetime along with the fines!!

Comments are closed.